The emergence of European requirements for safety reporting has resulted in
systems geared towards the timely collection and submission of reports at
the cost of the quality of the reports or their evaluation. This change in
focus has been engendered by system audits concentrating on 'easy to measur
e targets' such as time frames. The real purpose of pharmacovigilance. the
identification and communication of potential safety concerns, may be lost
in the effort to expedite. By common consensus there are certain safety iss
ues that warrant special attention including serious unexpected events, cha
nges in frequency of known adverse events, those involving special populati
ons, overdosage. or potential drug-drug interactions. Rationalizing and pri
oritizing workflow management during safety processing is required to optim
ize the utilization of available resources.
This paper provides a basis for discussion on suitable standards for the re
ceipt, processing and distribution of safety reports and proposes possible
benchmarks as a measurement of competent pharmacovigilance practice. Copyri
ght (C) 2000 John Wiley & Sons, Ltd.